Browse the evidence

Incretin-based therapies may attenuate intestinal iron absorption, independent of reduced intake, potentially contributing to iron deficiency in susceptible individuals.

Monitor iron levels if you have a history of anemia or low iron, as semaglutide may slightly reduce absorption.

Heterozygous variants in the POMC gene (specifically p.Arg90His, p.Ser94Gly, p.Ser94=, and p.Ala195=) are associated with an intermediate obesity phenotype in adults, likely due to haploinsufficiency affecting melanocortin peptide processing.

If you carry a heterozygous POMC variant, you may have an intermediate form of genetic obesity that responds differently to standard interventions. This information can help tailor your treatment plan, though functional validation of specific variants is still needed.

Tirzepatide as an adjunct to insulin in adults with Type 1 Diabetes and overweight/obesity produces significant body weight reduction and reduced insulin requirements, but current evidence is insufficient to establish durable glycaemic benefit or long-term safety.

For adults with Type 1 Diabetes and obesity, Tirzepatide is a promising tool for significant weight loss and reducing insulin needs. However, it is not yet proven to reliably improve long-term blood sugar control or safety. If used, it requires careful monitoring for side effects like nausea and potential risks like DKA, especially if insulin is reduced too aggressively. It is currently an investigational option, not a standard of care.

BPC-157 accelerates tissue repair (tendons, muscles, ligaments, GI mucosa) by stimulating angiogenesis and modulating inflammation, though it lacks FDA approval and robust human clinical trials.

BPC-157 is a peptide studied for its ability to speed up the healing of tendons, muscles, and gut lining. While animal studies show promising results for tissue repair, it is not yet approved by the FDA for human use. It is sometimes used off-label in sports medicine, but robust human clinical trials are still needed to confirm its safety and efficacy.

Carnivore and animal-based diets do not consistently improve athletic performance and may impair high-intensity exercise capacity due to reduced muscle glycogen and constrained metabolic flexibility.

Do not switch to a carnivore or animal-based diet expecting better performance, especially if your sport involves sprinting, lifting, or high-intensity intervals. These diets reduce muscle glycogen and make it harder to produce energy quickly. While you might lose weight or feel less bloated, your high-intensity performance will likely suffer. Stick to established sports nutrition guidelines that prioritize carbohydrate availability for intense training.

Carnivore and animal-based diets pose significant risks for micronutrient deficiencies, altered gut microbiota, and unfavorable lipid profiles, with no long-term safety data in athletes.

Be cautious with long-term carnivore or animal-based diets. You risk missing key nutrients like fiber, vitamin C, and magnesium, which can affect gut health and recovery. Your cholesterol levels might also rise significantly. There is no long-term safety data for athletes on these diets. If you choose to try it, monitor your blood work closely and consider it experimental, not optimal.

In specific preclinical models (OVX rats, T2D mice), high-dose GLP-1 agonists can improve bone mass and microarchitecture, but these effects require doses much higher than those approved for human obesity treatment.

Animal studies show GLP-1s *can* help bones, but only at doses far higher than what humans take. This suggests the drug itself isn't a 'bone builder' at standard doses, and the bone loss seen in humans is likely due to weight loss, not a direct toxic effect of the drug.

GABA signaling can induce the transdifferentiation of alpha cells into beta-like cells, potentially reversing chemically induced diabetes in vivo.

There is experimental evidence that GABA, a neurotransmitter, might help convert alpha cells (which raise blood sugar) into beta-like cells (which lower blood sugar) in diabetic mice. However, the paper also notes that other studies found no such regeneration with long-term GABA or artesunate administration. This remains a research area, not a current treatment option for humans.

Liraglutide shows a statistically significant disproportionality signal for completed suicide, but this is likely due to statistical fragility, small case numbers, and notoriety bias rather than a true pharmacological effect.

While Liraglutide shows a statistical signal for completed suicide in reporting databases, this is based on a very small number of cases (14) and is likely influenced by reporting bias. It should not be interpreted as evidence of increased risk.

Tirzepatide mitigates ischemic stroke damage by restoring Blood-Brain Barrier (BBB) integrity via Claudin-1 expression and reducing neuroinflammation.

This finding is currently limited to animal studies. While promising for stroke recovery, it does not yet translate to a standard human treatment protocol for acute stroke.

The high pricing of semaglutide (₹17,000–26,000/month) threatens equitable access.

Practitioners should be aware of the cost barriers that may limit patient access to semaglutide.

Bariatric surgery (RYGB, sleeve gastrectomy) does not result in clinically significant improvements in semen volume, sperm concentration, morphology, or DNA damage in men with obesity.

Do not expect bariatric surgery to improve your fertility. While it helps with weight, studies show it does not significantly improve sperm quality or DNA integrity. If fertility is a priority, lifestyle changes are a more reliable first step.

Non-peptide small molecule agonists targeting the GLP-1 receptor orthosteric site can achieve binding affinities and stability comparable to or exceeding existing peptide-based GLP-1RAs, suggesting a viable mechanism for oral administration.

This paper does not offer a current treatment but identifies potential oral drug candidates. It suggests that future oral GLP-1 medications may exist that are as effective as current injectables, addressing the common desire to avoid injections.

Self-administered overdose of Semaglutide (up to 8x the weekly dose) can cause multiorgan failure, including acute kidney injury, cholestatic liver dysfunction, and gastrointestinal bleeding, in patients with Type 2 Diabetes.

If you are using Semaglutide, never inject more than the prescribed weekly dose, even if you feel you need to 'catch up' or are experiencing side effects. The delivery pen allows you to inject multiple times, which can lead to life-threatening organ failure. If you feel dysphoric or suicidal, seek immediate help and do not attempt to self-medicate or overdose.

An intensive weight loss intervention combining total diet replacements (TDR), behavioral support, and weight loss medications (WLM) as needed achieves and maintains ≥20% weight loss in adults with obesity class I or II, significantly outperforming usual care.

To achieve significant weight loss (≥20%), you need a structured, long-term (2-year) program that combines strict initial calorie restriction (via meal replacements), regular coaching, and physical activity. If you don't lose enough weight in the first month, the program adds medication support. This is more intensive than typical 'eat less, move more' advice, which usually results in minimal weight loss.

Long-term use of FDA/Health Canada-approved obesity pharmacotherapies (semaglutide, tirzepatide, liraglutide, naltrexone-bupropion, orlistat) combined with health behavior changes produces clinically meaningful weight loss and prevents weight regain upon discontinuation.

If you have obesity (BMI ≥ 30, or ≥ 27 with health issues), talk to your doctor about FDA/Health Canada-approved weight loss medications like semaglutide or tirzepatide. These work best when combined with diet and exercise changes. Crucially, these are long-term treatments; stopping them usually leads to regaining the weight, so view them as a permanent tool for managing your health, not a quick fix.

Tirzepatide (5-15 mg weekly) produces superior weight loss compared to semaglutide and placebo in adults with obesity, with dose-dependent efficacy.

Tirzepatide is a weekly injection that can lead to significant weight loss (up to ~21% in trials). It works by targeting two hormones (GIP and GLP-1). Side effects like nausea are common but often temporary. It is approved for adults with obesity or overweight with health issues.

Combining resistance training with progressive whey protein supplementation (up to 60g/day) initiated 3 weeks post-surgery counteracts disproportional fat-free mass loss in patients undergoing metabolic bariatric surgery.

If you have had bariatric surgery, standard care may not be enough to protect your muscle. This protocol suggests starting resistance training (both home and supervised) and gradually increasing whey protein intake to 60g per day, starting 3 weeks after surgery. This combination aims to preserve muscle mass, which is crucial for long-term health and metabolic function.

A multidisciplinary group intervention combining nutritional education, physical activity, and emotional management promotes sustainable weight loss (5-10%) and improves quality of life in adults with obesity.

To manage obesity effectively, consider joining a structured group program that combines nutrition education, physical activity, and emotional support. Look for programs that meet weekly for about two months and include follow-up visits. The social aspect and focus on emotional well-being can help you stick to healthy habits long-term.

An intensive weight loss intervention combining total diet replacement (800-850 kcal/day), behavioral support, and weight loss medication achieves and maintains >20% weight loss and improves cardiometabolic risk in adults with severe obesity (BMI ≥35 kg/m²) over 2 years.

For severe obesity, standard 'eat less, move more' advice often fails. This protocol uses a 2-year structured approach: start with a very low-calorie formula diet (800-850 kcal) for 12 weeks with weekly support. If you don't lose enough weight, add a GLP-1 medication. Then, gradually transition to a healthy, low-calorie diet while maintaining exercise. The key is the intensive support and the ability to 'rescue' the plan with formula meals or medication if you regain weight.

Injectable semaglutide 2.4 mg once weekly produces significant weight loss (mean 15.2% over 104 weeks) and improves cardiometabolic risk factors in adults with obesity.

If you have obesity and struggle to lose weight through diet and exercise alone, ask your doctor about injectable semaglutide (2.4 mg once weekly). It is clinically proven to help you lose an average of 15% of your body weight over two years and improves heart health markers. Be prepared for a slow start to minimize stomach upset, and stick with it as the benefits are significant.

Implementing a structured, EHR-driven care process (PATHWEIGH) in primary care mitigates population-level weight gain and increases the likelihood of patients receiving weight-related care, even among those who do not receive direct clinical intervention.

If you are a healthcare system, stop waiting for patients to ask for help. Use your electronic health records to flag patients with high BMI and prompt doctors to discuss weight. Educate your staff that obesity is a chronic disease, not a lifestyle failure. This simple process change can help patients lose weight even if they never see a specialist.

Testosterone therapy in older men with low testosterone and symptoms improves sexual function, anemia, and bone mineral density, and prevents type 2 diabetes in high-risk men, while demonstrating cardiovascular safety in large RCTs.

If you are an older man with low testosterone and symptoms, testosterone therapy can improve sexual function, blood counts, and bone density. For those at high risk of diabetes, it significantly reduces that risk. Large recent studies confirm it is safe for the heart and prostate, so discuss this with your doctor if you meet the criteria.

Obesity pharmacotherapy reduces the risk of major adverse cardiovascular events (MACE) in patients with established atherosclerotic cardiovascular disease (ASCVD) and BMI ≥ 27, independent of diabetes status.

If you have heart disease and are overweight (BMI ≥ 27), ask your doctor about semaglutide (Wegovy). It has been proven to reduce the risk of heart attacks and strokes, in addition to helping with weight loss.